Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Alemtuzumab (MabCampath, Campath-1H) is a lymphocyte-depleting monoclonal antibody increasingly used in renal transplantation. This article reports the long-term follow-up data from the first series of patients treated with alemtuzumab for biopsy-proven acute rejection (BPAR). METHODS: Fifteen patients were identified who had received alemtuzumab for BPAR between November 1991 and June 1994. Patient and allograft survival were compared with a control group consisting of 25 patients with BPAR from the same era treated with intravenous methyl prednisolone, and with a contemporaneous UK renal transplant cohort. RESULTS: All rejection episodes responded to treatment with alemtuzumab but there was an excess of early infection-associated death in this group. Long-term transplant survival was similar in both groups as was allograft function (mean creatinine concentration at 10 years was 143 micromol/L in alemtuzumab cohort and 183 micromol/L in control cohort, P=0.06). There was no excess incidence of malignancy or cytomegalovirus infection in this prolonged follow-up period.

Original publication

DOI

10.1097/TP.0b013e31819d3353

Type

Journal article

Journal

Transplantation

Publication Date

15/04/2009

Volume

87

Pages

1092 - 1095

Keywords

Adolescent, Adult, Aged, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm, Antineoplastic Agents, Cadaver, Cohort Studies, Female, Follow-Up Studies, Graft Rejection, Humans, Kidney Failure, Chronic, Kidney Transplantation, Living Donors, Male, Methylprednisolone, Middle Aged, Time Factors, Tissue Donors